A detailed history of Hrt Financial LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Hrt Financial LP holds 16,943 shares of DNLI stock, worth $409,681. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,943
Holding current value
$409,681
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$20.96 - $31.05 $355,125 - $526,080
16,943 New
16,943 $493,000
Q4 2023

Feb 09, 2024

BUY
$16.2 - $23.18 $519,809 - $743,776
32,087 Added 262.9%
44,292 $950,000
Q3 2023

Nov 13, 2023

BUY
$20.63 - $30.17 $251,789 - $368,224
12,205 New
12,205 $251,000
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $1.4 Million - $2.08 Million
54,028 Added 228.93%
77,628 $2.38 Million
Q2 2022

Aug 12, 2022

BUY
$20.88 - $35.19 $492,768 - $830,484
23,600 New
23,600 $694,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.